Bucking the Trend | GenomeWeb

Bucking the Trend

This may mess up your "merger madness" bracket (kind of like Villanova is doing for the basketball brackets): Eli Lilly is not interested in a merger with Bristol-Myers Squibb, reports the Financial Times. CEO John Lechleiter told the FT that he'd rather "work to boost his company's internal development of experimental medicines alongside selective smaller-scale deals."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.